2696 — Shanghai Henlius Biotech Share News
0.000.00%
Last trade - 00:00- HK$35.72bn
- HK$39.39bn
- CNY6.67bn
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln
Sandoz rises as Shanghai Henlius Biotech collaboration adds up to 10 biosimilars
Shanghai Henlius Biotech climbs on Sandoz licensing deal
Swiss stocks - Factors to watch on August 17
Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech (updated)
Shanghai Henlius Biotech, Sandoz sign pact to collaborate
Brief: Sandoz Announces Strategic Collaboration With Henlius On Up To 10 Biosimilars
Analysis: Chinese drugmakers with big ambitions struggle to recruit staff for global expansion
Brief: Shanghai Henlius Biotech Says Unit's Hanbeiyou (Pertuzumab Injection) Passes GMP Inspection
Brief: Shanghai Henlius Biotech Says Phase 3 Study Of HLX04-O For WAMD Meets Primary Endpoint
Brief: Shanghai Henlius Biotech Says Nmpa Approves NDA For Hansizhuang For Treatment Of Gastric Cancer
Brief: Fosun Pharma Says Henlius Biotech's Pertuzumab Injection Approved By China Regulator
Brief: Shanghai Henlius Biotech Inc Says Serplulimab Receives Positive CHMP Opinion
Brief: Shanghai Henlius Biotech Permitted To Commence HLX43 Phase 2/3 Trial For Advanced Squamous NSCLC In Japan
Brief: Shanghai Henlius Biotech Says Phase 2/3 Trial Of HLX07 With Hansizhuang For Advanced SQNSCLC Approved To Commence In Australia
Brief: Shanghai Henlius Biotech Says NMPA Approves Trial Application Colorectal Cancer Injection